Coherus Biosciences | CHRS - Ordinary Share Capital


Coherus Biosciences reported $121.16M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 608K Jun/2026
Acadia Pharmaceuticals USD 172.31M 174K Sep/2026
Akebia Therapeutics USD 265.42M 199K Dec/2025
ALKERMES USD 168.03M 489K Sep/2026
Alnylam Pharmaceuticals USD 133.88M 141K Sep/2026
Amarin USD 20.81M 13K Dec/2025
Amgen USD 541M 0 Sep/2026
Baxter International USD 517M 549K Jun/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.68M 141K Sep/2026
Bristol-Myers Squibb USD 2.04B 7M Jun/2026
Coherus Biosciences USD 121.16M 4.92M Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Fujifilm JPY 1.2B 476K Sep/2026
Gilead Sciences USD 1.24B 1000K Jun/2026
Ironwood Pharmaceuticals USD 160K 0 Dec/2024
Merck USD 2.47B 1.05M Jun/2026
Myriad Genetics USD 93.5M 400K Dec/2025
Pacira USD 39.9M 75K Sep/2026
Perrigo USD 138.8M 700K Sep/2026
Pfizer USD 5.7B 1000K Sep/2026
PTC Therapeutics USD 83.33M 445K Jun/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Sarepta Therapeutics USD 107.23M 1.61M Sep/2026
Teva Pharmaceutical Industries USD 1.17B 2M Sep/2026
Vertex Pharmaceuticals USD 253.5M 200K Sep/2026
Xencor USD 74.33M 265K Jun/2026
Zoetis USD 407.49M 6.67M Sep/2026